Pharming Group (OTCMKTS:PHGUF) Hits New 1-Year High – Here’s What Happened

Pharming Group NV (OTCMKTS:PHGUF) reached a new 52-week high during trading on Friday . The company traded as high as $1.85 and last traded at $1.85, with a volume of 450 shares trading hands. The stock had previously closed at $1.65.

Pharming Group Stock Up 12.1%

The company has a debt-to-equity ratio of 0.46, a current ratio of 3.16 and a quick ratio of 2.39. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of 185.19 and a beta of 0.37. The firm’s 50-day moving average is $1.63 and its 200 day moving average is $1.43.

Pharming Group (OTCMKTS:PHGUF) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.01 EPS for the quarter. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The firm had revenue of $97.30 million for the quarter, compared to analyst estimates of $80.18 million.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.